Modifiable health behaviors among low-income, uninsured men with prostate cancer.
CONCLUSIONS: Most men in this cohort of low-income, uninsured CaP survivors did not engage the healthy behaviors promulgated by the American Cancer Society. Future interventions in this population should focus on encouraging and facilitating healthier lifestyle choices in physical activity, diet, and weight management. PMID: 32624421 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - July 2, 2020 Category: Urology & Nephrology Authors: Haymer M, Connor SE, Kwan L, Litwin MS Tags: Urol Oncol Source Type: research

Long-term outcomes of incidental prostate cancer at radical cystectomy.
CONCLUSIONS: In a large RC series, we note a 20% rate of incidental PCa, the majority of which are clinically insignificant. On long-term follow-up, we determined that BCR and PCa mortality are extremely rare events among these patients. Pending validation, future guidelines may consider omission of PCa surveillance for some patients with incidental PCa at RC. PMID: 32624422 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - July 2, 2020 Category: Urology & Nephrology Authors: Packiam VT, Tsivian M, Avulova S, Sharma V, Tarrell R, Cheville JC, Frank I, Thompson RH, Tollefson MK, Gettman MT, Karnes RJ, Thapa P, Boorjian SA Tags: Urol Oncol Source Type: research

Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.
Abstract OBJECTIVES: The net oncogenic effect of β2-adrenergic receptor ADRB2, whose downstream elements induce neuroendocrine differentiation and whose expression is regulated by EZH2, is unclear. ADRB2 expression and associated clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) are unknown. METHODS AND MATERIALS: This was a retrospective analysis of a multi-center, prospectively enrolled cohort of mCRPC patients. Metastatic biopsies were obtained at progression, and specimens underwent laser capture microdissection and RNA-seq. ADRB2 expression was stratified by histology and ...
Source: Urologic Oncology - July 2, 2020 Category: Urology & Nephrology Authors: Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN, Thomas GV, Li P, Lui A, Small EJ, Aggarwal RR Tags: Urol Oncol Source Type: research

Prognostic significance of serum lactate dehydrogenase in patients undergoing radical cystectomy for bladder cancer.
Abstract BACKGROUND: To investigate the prognostic significance of preoperative serum lactate dehydrogenase (LDH) in patients undergoing radical cystectomy for bladder cancer (BCa). PATIENTS AND METHODS: A cohort of 263 patients undergoing open or laparoscopic radical cystectomy between 2011 and 2016 was studied. Baseline characteristics, hematological variables, follow-up data were collected. Kaplan-Meier curves and Cox proportional hazard regression model were applied to assess the relationship between LDH and overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). RESUL...
Source: Urologic Oncology - July 2, 2020 Category: Urology & Nephrology Authors: Su S, Liu L, Sun C, Yang L, Nie Y, Chen Y, Zhang J, Li S Tags: Urol Oncol Source Type: research

Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy.
Abstract OBJECTIVES: Empirically dosed enoxaparin is routinely given in the postoperative period for venous thromboembolism (VTE) prophylaxis after radical cystectomy (RC). Patient-specific factors may alter its pharmacokinetics, and it is unclear whether this leads to levels sufficient for antithrombosis. We sought to evaluate variability of anti-factor Xa levels in a cohort of RC patients receiving perioperative enoxaparin prophylaxis. MATERIAL AND METHODS: Patients undergoing RC at a single institution were placed on a postoperative pathway that included enoxaparin. An anti-factor Xa level was drawn 2 to 4...
Source: Urologic Oncology - July 2, 2020 Category: Urology & Nephrology Authors: Corona LE, Singhal U, Hafez K, Herrel LA, Kaffenberger SD, Montgomery JS, Morgan TM, Weizer AZ, Qin Y, Ambani SN Tags: Urol Oncol Source Type: research

Recent scenario of long non-coding RNAs as a diagnostic and prognostic biomarkers of prostate cancer.
Abstract Prostate cancer (CaP) is a leading cause of cancer deaths in the worldwide with broad range of clinical manifestations ranging from relatively indolent to aggressive metastasis. Altered expression of many circulating long non-coding RNAs (lncRNAs), known to have role in tumorigenesis and metastasis, have already been reported in CaP patients. These lncRNAs modulate CaP pathogenesis by modulating multiple genes and thus altering metabolic pathways. Sustained androgen receptor (AR) signaling is one such key feature of castration-resistant prostate cancer, a CaP stage that has unmet need of accurate diagnost...
Source: Urologic Oncology - July 1, 2020 Category: Urology & Nephrology Authors: Shukla KK, Misra S, Sankanagoudar S, Sharma H, Choudhary GR, Pareek P, Vishnoi JR, Sharma P Tags: Urol Oncol Source Type: research

Overexpression of lncRNA TINCR is associated with high-grade, invasive, and recurring tumors, and facilitates proliferation in vitro and in vivo of urothelial carcinoma of the bladder.
CONCLUSIONS: Up-regulation of TINCR may act as an unfavorable indicator for the diseasing status of UCB. TINCR facilitates bladder cancer proliferation in vitro and in vivo. Hsa-miR-125b is a target for TINCR in UCB. PMID: 32622721 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - July 1, 2020 Category: Urology & Nephrology Authors: Han Y, Sun G Tags: Urol Oncol Source Type: research

The cost of obesity in radical cystectomy.
Abstract INTRODUCTION: The prevalence of obesity is on the rise in the Unites States, and obesity has been associated with increased complications and costs in a variety of complex surgeries. However, the contribution of obesity to the overall costs of radical cystectomy has not been studied in detail using contemporary data. Our objective is to assess the variation in healthcare costs due to obesity on the index hospitalization for radical cystectomy in the United States between 2003 and 2015. MATERIALS AND METHODS: This was a retrospective cohort study, using the Premier Healthcare Database, of 1,242 patien...
Source: Urologic Oncology - June 30, 2020 Category: Urology & Nephrology Authors: Huynh MJ, Wang Y, Chang SL, Tully KH, Chung BI, Wright JL, Mossanen M Tags: Urol Oncol Source Type: research

Practice patterns for extended venous thromboembolism chemoprophylaxis among urologic oncologists after radical cystectomy.
CONCLUSIONS: The majority of surveyed urologic oncologists are prescribing subcutaneous enoxaparin ECP following RC. Poor patient adherence due to self-injections and financial barriers were frequently reported and represent a possible opportunity for the use of oral anticoagulants in the post-operative setting. These data will be used in the development of a proposed clinical trial of a DOAC in the post-RC setting. PMID: 32616422 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 29, 2020 Category: Urology & Nephrology Authors: Dall CP, Shaw N, Egan J, Carvalho FL, Galloway LAS, Krasnow R, Stamatakis L Tags: Urol Oncol Source Type: research

Comparative efficacy of apalutamidedarolutamide and enzalutamidefor treatment of nonmetastatic castrate-resistant prostate cancer: Asystematic review and network meta-analysis.
CONCLUSION: Enzalutamide and apalutamide had similar and higher MFS rate in indirect comparison with darolutamide. In cases where AEs are concerning, darolutamide might be the preferred agent. PMID: 32605736 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 28, 2020 Category: Urology & Nephrology Authors: Kumar J, Jazayeri S, Gautam S, Norez D, Alam MU, Tanneru K, Bazargani S, Costa J, Bandyk M, Ganapathi H, Koochekpour S, Balaji KC Tags: Urol Oncol Source Type: research

Introduction: Personalizing risk stratification in bladder cancer: Moving away from "the eyeball test" and embracing objective quantification of risk.
Introduction: Personalizing risk stratification in bladder cancer: Moving away from "the eyeball test" and embracing objective quantification of risk. Urol Oncol. 2020 Jun 27;: Authors: Psutka SP PMID: 32600927 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 27, 2020 Category: Urology & Nephrology Authors: Psutka SP Tags: Urol Oncol Source Type: research

Downregulation of RUNX3 has a poor prognosis and promotes tumor progress in kidney cancer.
CONCLUSION: Targeting RUNX3 pathway and its promoter methylation are potential therapeutic strategies to treat kidney cancer. PMID: 32600926 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 26, 2020 Category: Urology & Nephrology Authors: Zheng J, Mei Y, Zhai G, Zhao N, Jia D, Fan Y Tags: Urol Oncol Source Type: research

Pathological findings at radical prostatectomy of biopsy na ïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
CONCLUSION: In biopsy naïve patients treated with RP, TB achieved higher rates of ISUP GG concordance, but same percentages of csPCa missed, compared to SB. Moreover, only patients with ISUP GG ≥2, but not patients with ISUP GG1, exhibited higher concordance rates. Finally, age, MCCI, MCCL, PSA-D, and lesion location were associated with concordance between TB and RP. PMID: 32600928 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 26, 2020 Category: Urology & Nephrology Authors: Luzzago S, Petralia G, Maresca D, Sabatini I, Cordima G, Brescia A, Verweij F, Garelli G, Mistretta FA, Cioffi A, Pricolo P, Alessi S, Ferro M, Matei DV, Renne G, de Cobelli O, Musi G Tags: Urol Oncol Source Type: research

Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer.
CONCLUSION: The combination of 177Lu-J591 delivered as a single fractionated cycle with docetaxel/prednisone is feasible in patients with mCRPC. Without preselection for prostate-specific membrane antigen, accurate targeting of known sites of disease and a strong preliminary efficacy signal was observed. PMID: 32600929 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 26, 2020 Category: Urology & Nephrology Authors: Batra JS, Niaz MJ, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, Osborne J, Bander NH, Tagawa ST Tags: Urol Oncol Source Type: research

Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer.
CONCLUSIONS: Machine learning algorithms can improve our ability to predict bladder cancer prognosis. Compared to CPH models, ANNs predicted OS more accurately and DSS with similar accuracy. Given the inherent limitations of administrative datasets, machine learning may allow for optimal interpretation of the complex data they contain. PMID: 32593506 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 24, 2020 Category: Urology & Nephrology Authors: Bhambhvani HP, Zamora A, Shkolyar E, Prado K, Greenberg DR, Kasman AM, Liao J, Shah S, Srinivas S, Skinner EC, Shah JB Tags: Urol Oncol Source Type: research

Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer.
Abstract Prostate cancer is one of the most common causes of death in males. Even if treatment is often of curative intent in early stages of the disease, up to 50% of patients relapse after primary therapy. Moreover, 10% to 15% of patients present in a primary metastatic stage of disease. In the past years the treatment landscape of metastatic castration-resistant prostate cancer expanded due to the development of second-generation antiandrogens (abiraterone acetate, enzalutamide), chemotherapeutic agents and radium-223. With the availability of several therapeutic lines, we are now confronted with the problem of...
Source: Urologic Oncology - June 23, 2020 Category: Urology & Nephrology Authors: Kafka M, Eder IE, Klocker H, Heidegger I Tags: Urol Oncol Source Type: research

The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
CONCLUSION: The role of CN remains controversial. We found no difference in survival outcomes between patients treated with and without CN before TKI therapy. However, CN was associated with improved survival in specific patient subgroups. Tailored, individualized treatment is key to further improve oncological outcomes for mRCC. PMID: 32576526 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 21, 2020 Category: Urology & Nephrology Authors: Janisch F, Hillemacher T, Fuehner C, D'Andrea D, Meyer CP, Klotzbücher T, Kienapfel C, Vetterlein MW, Kimura S, Abufaraj M, Dahlem R, Shariat SF, Fisch M, Rink M Tags: Urol Oncol Source Type: research

Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer.
CONCLUSIONS: The addition of PSAD improves the predictive performance of PI-RADS in men without known prostate cancer. A PSAD threshold of 0.15 can help to minimize the number of missed clinically significant prostate cancer cases in men with a PI-RADS score of 3 or lower who decide to defer biopsy. PMID: 32576527 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 21, 2020 Category: Urology & Nephrology Authors: Stevens E, Truong M, Bullen JA, Ward RD, Purysko AS, Klein EA Tags: Urol Oncol Source Type: research

D2-40/podoplanin expression in cancer stroma by immunohistochemical staining is associated with poor prognosis in bladder cancer patients after radical cystectomy.
Abstract OBJECTIVES: We assessed whether D2-40/podoplanin (PDPN) could be used to identify bladder cancer patients with a higher probability of benefiting from cisplatin-based combination chemotherapy. PATIENTS AND METHODS: We investigated PDPN expression by immunohistochemical analysis of cystectomy specimens from 96 bladder cancer patients who had undergone radical cystectomy without neoadjuvant or adjuvant cisplatin-based combination chemotherapy until recurrence. We classified the cases into 2 groups according to the achievement of 2-year recurrence-free survival (RFS) and evaluated whether PDPN expressio...
Source: Urologic Oncology - June 20, 2020 Category: Urology & Nephrology Authors: Okajima E, Tomizawa M, Shimada K, Negishi T, Nishiyama N, Kitamura H Tags: Urol Oncol Source Type: research

Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice.
Abstract PURPOSE: To assess the impact of RTOG-9601 and GETUG-AFU-16 on the routine use of combination androgen deprivation therapy (ADT) with postoperative radiotherapy (PORT) for prostate cancer (CaP). MATERIAL AND METHODS: Patients with localized CaP treated with radical prostatectomy (RP) and PORT with or without ADT at a comprehensive cancer center from January 2006 to June 2007 (Period 1 = P1), July 2011 to December 2012 (Period 2 = P2), and January 2017 to June 2018 (Period 3 = P3) were included. Clinicopathologic features and treatment characteristics were analyzed and compared. Multivaria...
Source: Urologic Oncology - June 15, 2020 Category: Urology & Nephrology Authors: Sanmamed N, Glicksman RM, Herrera-Caceres J, Lehrer EJ, Heaton J, Hansen AR, Chung P, Fleshner NE, Den RB, Zaorsky NG, Berlin A Tags: Urol Oncol Source Type: research

Prospective development of a prostate cancer risk calculator in a racially diverse population: The Kaiser Permanente Prostate Cancer Risk Calculator.
CONCLUSIONS: In men with elevated PSA levels, our calculator provides useful information that may enhance the shared decision-making process regarding the need for biopsy. PMID: 32536468 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 12, 2020 Category: Urology & Nephrology Authors: Presti J, Alexeeff S, Horton B, Prausnitz S, Avins AL Tags: Urol Oncol Source Type: research

Oncologic outcomes of laparoscopic radical nephroureterectomy in conjunction with template-based lymph node dissection: An extended follow-up study.
This study investigated the relapse pattern and oncologic outcomes after laparoscopic nephroureterectomy with template-based lymph node dissection (LND) in patients with clinically node-negative (cN0) upper urinary tract urothelial carcinoma. The frequency of lymph node metastasis, including micrometastases, was also evaluated. METHODS AND MATERIALS: A total of 105 patients with cTa-3N0M0 upper urinary tract urothelial carcinoma were analyzed, all of whom underwent regional LND during laparoscopic nephroureterectomy. Of those patients, 96 (91%) underwent complete LND in accordance with an anatomical template-based rul...
Source: Urologic Oncology - June 10, 2020 Category: Urology & Nephrology Authors: Matsumoto R, Abe T, Takada N, Minami K, Harabayashi T, Nagamori S, Hatanaka KC, Yamashiro K, Kikuchi H, Osawa T, Maruyama S, Shinohara N Tags: Urol Oncol Source Type: research

MicroRNA profile in stage I clear cell renal cell carcinoma predicts progression to metastatic disease.
This study sought to identify microRNA (miRNA) profiles of small, pathologically confirmed stage 1 clear cell renal cell carcinoma (ccRCC) tumors that are associated with progression to metachronous metastatic disease. MATERIALS AND METHODS: Fifty-five pathologic stage 1 ccRCC tumors ≤5cm, from 2 institutions, were examined in a miRNA screening, followed by a validation study. For the screening phase 752 miRNA were evaluated on each sample to identify those with differential expression between tumors that subsequently did (n = 10) or did not (n = 10) progress to metastatic disease. For the validation, 35 ad...
Source: Urologic Oncology - June 10, 2020 Category: Urology & Nephrology Authors: Moynihan MJ, Sullivan TB, Burks E, Schober J, Calabrese M, Fredrick A, Kalantzakos T, Warrick J, Canes D, Raman JD, Rieger-Christ K Tags: Urol Oncol Source Type: research

Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays.
CONCLUSIONS: The study demonstrated that ddPCR assays could be used to detect cftDNA in liquid biopsy monitoring of the post-therapy disease status in patients with UC. Overall, 70% of the patients in our study harbored mutations that were assayable by ddPCR. PMID: 32532529 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 9, 2020 Category: Urology & Nephrology Authors: Pritchard JJG, Hamilton G, Hurst CD, Fraser S, Orange C, Knowles MA, Jones RJ, Leung HY, Iwata T Tags: Urol Oncol Source Type: research

The utility of intraoperative contrast-enhanced ultrasound in detecting residual disease after focal HIFU for localized prostate cancer.
CONCLUSION: CEUS has a higher added value compared to early mpMRI in ruling out clinically significant cancer after focal HIFU. It should be evaluated whether the use of CEUS intraoperatively enhances the efficacy of focal HIFU. PMID: 32532530 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 9, 2020 Category: Urology & Nephrology Authors: Bacchetta F, Martins M, Regusci S, Jichlinski P, Meuwly JY, Lucca I, Valerio M Tags: Urol Oncol Source Type: research

MiR-486-5p enhances cisplatin sensitivity of human muscle-invasive bladder cancer cells by induction of apoptosis and down-regulation of metastatic genes.
CONCLUSION: Altogether, these results indicated that the miRNA-486-5p could induce apoptosis and inhibit cell migration ability of the cells. It seems that pre-electroporation of cells with miRNA-486-5p has useful results in the enhancement of cisplatin sensitivity of 5637 and EJ138 cancer cells and this combination may be a promising treatment strategy for bladder cancer therapy. PMID: 32527702 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - June 8, 2020 Category: Urology & Nephrology Authors: Salimian J, Baradaran B, Azimzadeh Jamalkandi S, Moridikia A, Ahmadi A Tags: Urol Oncol Source Type: research

A systematic review and meta-analysis of magnetic resonance imaging and ultrasound guided fusion biopsy of prostate for cancer detection-Comparing transrectal with transperineal approaches.
Abstract Targeted biopsy using multiparametric magnetic resonance imaging increases the detection rate of clinically significant prostate cancer (csCaP). In this meta-analysis, we compare the diagnostic accuracy of transrectal (TR) vs transperineal (TP) approaches for MRI-guided software fusion biopsy (FB) in the detection of csCaP. A literature search was performed in PubMed, Cochrane and Embase electronic databases up until July 2019 following the preferred reporting items for systematic review and meta-analysis system. The pooled sensitivity and specificity of either approach was evaluated using radical prostat...
Source: Urologic Oncology - June 3, 2020 Category: Urology & Nephrology Authors: Loy LM, Lim GH, Leow JJ, Lee CH, Tan TW, Tan CH Tags: Urol Oncol Source Type: research

Estrogen receptors in urogenital schistosomiasis and bladder cancer: Estrogen receptor alpha-mediated cell proliferation.
os LL Abstract Estrogen-like metabolites have been identified in S. haematobium, the helminth parasite that causes urogenital schistosomiasis (UGS) and in patients´ blood and urine during UGS. Estrogen receptor (ER) activation is enriched in the luminal molecular subtype bladder cancer (BlaCa). To date, the significance of ER to these diseases remains elusive. We evaluated ERα and ERβ expression in UGS-related BlaCa (n = 27), UGS-related non-malignant lesions (n = 35), and noninfected BlaCa (n = 80). We investigated the potential of ERα to recognize S. haematobium-derived metabol...
Source: Urologic Oncology - June 2, 2020 Category: Urology & Nephrology Authors: Bernardo C, Santos J, Costa C, Tavares A, Amaro T, Marques I, Gouveia MJ, Félix V, Afreixo V, Brindley PJ, Costa JM, Amado F, Helguero L, Santos LL Tags: Urol Oncol Source Type: research

MMPs, tyrosine kinase signaling and extracellular matrix proteolysis in kidney cancer.
Abstract Patients diagnosed with metastatic renal cell carcinoma (RCC) have ∼12% chance for 5-year survival. The integrity of the extracellular matrix (ECM) that surrounds tumor cells influences their behavior and, when disturbed, it could facilitate local invasion and spread of tumor cells to distant sites. The interplay between von Hippel-Lindau/hypoxia inducible factor signaling axis and activated kinase networks results in aberrant ECM and tumor progression. Matrix metalloproteinases (MMPs) are proteolytic enzymes implicated in ECM remodeling, tumor angiogenesis, and immune cell infiltration. Understanding...
Source: Urologic Oncology - May 31, 2020 Category: Urology & Nephrology Authors: Hashmi F, Mollapour M, Bratslavsky G, Bourboulia D Tags: Urol Oncol Source Type: research

Oncological control following partial gland ablation for intermediate-risk prostate cancer.
Abstract Historically, the primary objection to partial gland ablation (PGA) for management of prostate cancer (CaP) has been disease multifocality and inability to localize significant disease. Improved disease localization and risk stratification with multiparametric magnetic resonance imaging and targeted biopsy, along with its minimal adverse impact on quality of life has enabled PGA to gain acceptance. Today, the primary barrier for adopting PGA is its unknown oncological outcomes. Objectives of this review are to provide a rationale for PGA for managing intermediate-risk (IR) CaP; review oncological outcomes...
Source: Urologic Oncology - May 30, 2020 Category: Urology & Nephrology Authors: Becher E, Lepor H Tags: Urol Oncol Source Type: research

Radiation therapy in the management of the inguinal region in penile cancer: What's the evidence?
In this report, we review the current literature and further investigated the landscape of radiation sensitivity in nodal metastases of PeCa utilizing our well-established genome-based radiosensitivity index (RSI) platform. We hypothesized that optimal therapeutic gain could be achieved in PeCa stratified by the combination of clinicopathological parameters, genomic heterogeneity, and RSI-based radiation dose prescription (RxRSI). Similar to primary PeCa lesions, we found that the majority of PeCa nodal metastases are genomically radioresistant with significant heterogeneity. RxRSI should be considered to inform and optimi...
Source: Urologic Oncology - May 29, 2020 Category: Urology & Nephrology Authors: Yuan Z, Yang GQ, Ahmed KA, Torres-Roca JF, Spiess PE, Johnstone PA Tags: Urol Oncol Source Type: research

The effect of urinary diversion on long-term kidney function after cystectomy.
Abstract OBJECTIVES: Cystectomy with urinary diversion is associated with decreased long-term kidney function due to several factors. One factor that has been debated is the type of urinary diversion used: ileal conduit (IC) vs. neobladder (NB). We tested the hypothesis that long-term kidney function will not vary by type of urinary diversion. METHODS AND MATERIALS: We retrospectively identified all patients who underwent cystectomy with urinary diversion at our institution from January 1, 2007, to January 1, 2018. Data were collected on patient demographics, comorbid conditions, perioperative radiotherapy, a...
Source: Urologic Oncology - May 29, 2020 Category: Urology & Nephrology Authors: Faraj KS, Mi L, Eversman S, Singh R, DeLucia NM, Blodgett G, Swanson SK, Andrews PE, Ferrigni RG, Humphreys MR, Castle EP, Tyson MD Tags: Urol Oncol Source Type: research

Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry.
Abstract INTRODUCTION: Androgen deprivation therapy (ADT) remains the mainstay of treatment for metastatic prostate cancer (mPCa) but is associated with significant morbidities. Comparisons of medical castration (MC) and surgical orchidectomy (SO) have yielded varied results. We aimed to evaluate the oncological outcomes, adverse effect (AE) profiles and costs of MC and SO in patients with mPCa. METHODS AND MATERIALS: We reviewed 523 patients who presented with de novo mPCa from a prospectively maintained prostate cancer database over 15 years (2001-2015). All patients received ADT (either MC or SO) within 3 ...
Source: Urologic Oncology - May 29, 2020 Category: Urology & Nephrology Authors: Tan YG, Poon RJ, Pang LJ, Villanueva A, Huang HH, Chen K, Ng TK, Tay KJ, Ho HS, Yuen JS Tags: Urol Oncol Source Type: research

External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study.
;re T Abstract OBJECTIVE: To validate a nomogram predicting lymph node invasion (LNI) in prostate cancer patients undergoing radical prostatectomy taking into consideration multiparametric-magnetic resonance imaging (mp-MRI) parameters and targeted biopsies in a western European cohort. PATIENTS AND METHODS: A total of 473 men diagnosed by targeted biopsies, using software-based MRI-ultrasound image fusion system, and operated by radical prostatectomy with extended pelvic lymph node dissection across 11 Europeans centers between 2012 and 2019 were identified. Area under the curve of the receiver operator char...
Source: Urologic Oncology - May 25, 2020 Category: Urology & Nephrology Authors: Diamand R, Oderda M, Albisinni S, Fourcade A, Fournier G, Benamran D, Iselin C, Fiard G, Descotes JL, Assenmacher G, Svistakov I, Peltier A, Simone G, Di Cosmo G, Roche JB, Bonnal JL, Van Damme J, Rossi M, Mandron E, Gontero P, Roumeguère T Tags: Urol Oncol Source Type: research

Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells.
CONCLUSIONS: These data demonstrate that treatment with ARN-509 leads to increased autophagy levels in LNCaP cells. Furthermore, in combination with autophagy inhibitors, ARN-509 provided a significantly elevated antitumor effect, thus providing a new therapeutic approach potentially translatable to patients. PMID: 32466878 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 25, 2020 Category: Urology & Nephrology Authors: Eberli D, Kranzbühler B, Mortezavi A, Sulser T, Salemi S Tags: Urol Oncol Source Type: research

Sarcopenia in urologic oncology: Identification and strategies to improve patient outcomes.
Abstract Sarcopenia is the loss of muscle mass and function related to aging, undereating, disease conditions, or inactivity. Pre-existing sarcopenia diminishes the functional reserve of patients with cancer which increases their risk for frailty, cancer cachexia, and worse outcomes from treatments. The pathogenesis of sarcopenia is multi-factorial: opening opportunities for clinicians to work across disciplines to improve patient outcomes and quality of life. The purpose of this essay is to describe sarcopenia, discuss clinical screening and assessment for sarcopenia, and highlight potential interventions to mana...
Source: Urologic Oncology - May 24, 2020 Category: Urology & Nephrology Authors: Robertson HL, Michel C, Bartl L, Hamilton-Reeves JM Tags: Urol Oncol Source Type: research

Assessments of frailty in bladder cancer.
CONCLUSIONS: There is no universally agreed upon frailty assessment, but the most studied in radical cystectomy is the modified Frailty Index, providing valuable data with which to counsel patients preoperatively. Alterations in immune phenotypes provide potential future diagnostic biomarkers for frailty. PMID: 32451229 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 22, 2020 Category: Urology & Nephrology Authors: Grimberg DC, Shah A, Molinger J, Whittle J, Gupta RT, Wischmeyer PE, McDonald SR, Inman BA Tags: Urol Oncol Source Type: research

Examining the association of health literacy and numeracy with prostate-related knowledge and prostate cancer treatment regret.
In this study, we assess the association between health literacy, numeracy, prostate-related knowledge and treatment regret in a diverse population. MATERIALS AND METHODS: Patients obtaining care between June and August of 2016 at both community-based and academic tertiary care facilities were assessed for health literacy and numeracy using validated instruments. Prostate knowledge was tested in those patients without a history of prostate cancer using a 29-item questionnaire and patient-level predictors of knowledge were assessed. Prostate cancer treatment regret was assessed in those patients who had a history of pr...
Source: Urologic Oncology - May 21, 2020 Category: Urology & Nephrology Authors: Joyce DD, Heslop DL, Umoh JI, Brown SD, Robles JA, Wallston KA, Moses KA Tags: Urol Oncol Source Type: research

Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels.
Abstract PURPOSE: Choriocarcinoma germ cell tumors are rare and usually present with significantly elevated human chorionic gonadotropin (hCG) levels. When curable, it is felt to be largely a result of chemotherapy. We sought to determine the histologic characteristics for those undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) and compare them with metastatic nonseminomatous germ cell tumor (NSGCT) patients with similarly elevated hCG levels. METHODS: We reviewed medical records of men undergoing PC-RPLND between 1988 and 2017 with postorchiectomy, preinduction chemotherapy hCG lev...
Source: Urologic Oncology - May 21, 2020 Category: Urology & Nephrology Authors: Speir RW, Calaway AC, Einhorn LH, Foster RS, Cary C Tags: Urol Oncol Source Type: research

Predictors of adequate lymph node dissection in patients with non-muscle invasive bladder cancer undergoing radical cystectomy and effect on survival.
Abstract INTRODUCTION: Radical cystectomy (RC) is the standard of care for refractory high-risk non-muscle invasive bladder cancer (NMIBC). We aim to identify predictors of adequate lymph node dissection (LND) in a cohort of NMIBC patients undergoing RC, as well as its impact on clinical outcomes. METHODS: The National Cancer Database was queried for patients who underwent RC for urothelial cell carcinoma for clinical stage Tis/a/1 N0M0 disease between 2004 and 2013. Patients were stratified by LND: none, inadequate (
Source: Urologic Oncology - May 20, 2020 Category: Urology & Nephrology Authors: Lenis AT, Lec PM, Michel J, Brisbane W, Golla V, Sharma V, Gollapudi K, Blumberg J, Chamie K Tags: Urol Oncol Source Type: research

Rise in serum folate after androgen deprivation associated with worse prostate cancer-specific survival.
CONCLUSION: Our study suggests that men with substantial rises in folate after initiating ADT may be associated with worse prostate cancer-specific and overall survival. Our translational experiments in mice confirmed correlation between rising in folate levels post-castration. Given this study, further investigation is warranted on the role of dietary folate consumption during initiation of ADT and progression to castrate-resistant prostate cancer. PMID: 32444177 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 20, 2020 Category: Urology & Nephrology Authors: Liss MA, Ashcraft K, Satsangi A, Bacich D Tags: Urol Oncol Source Type: research

Chromophobe renal cell carcinoma: New genetic and metabolic insights.
Abstract Chromophobe renal cell carcinoma (chRCC) represents 5% of all RCC. ChRCC appears to arise from the distal nephron, in contrast to clear cell RCC that arises from the proximal nephron. ChRCC is distinctive because the tumor cells contain abundant abnormal mitochondria, and frequently have loss of one copy of multiple chromosomes, with a low rate of somatic mutations. Here, we focus on recent discoveries related to genetic and metabolic factors that may promote the progression of chRCC and summarize how these findings may relate to the prognosis and treatment of chRCC. PMID: 32444178 [PubMed - as suppl...
Source: Urologic Oncology - May 19, 2020 Category: Urology & Nephrology Authors: Zhang L, Henske EP Tags: Urol Oncol Source Type: research

Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.
CONCLUSION: In m-papRCC patients treated with first agent VEGFR-TKIs, the presence of BM is an unfavorable prognostic factor, associated with shorter PFS and OS. PMID: 32430250 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 17, 2020 Category: Urology & Nephrology Authors: Haaker L, Tryssesoone L, Renders I, Verbiest A, Lerut E, Baldewijns M, Bourgain C, Roussel E, Van den Bulck H, Wynendaele W, Laguerre B, Rioux-Leclercq N, Oudard S, Laenen A, Debruyne PR, Albersen M, Beuselinck B Tags: Urol Oncol Source Type: research

The contrasting roles of Dysferlin during tumor progression in renal cell carcinoma.
CONCLUSION: DYSF mRNA and protein expression are opposingly involved in tumor progression of ccRCC. DYSF could be used as a prognostic biomarker to predict survival of patients with ccRCC. PMID: 32430251 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 17, 2020 Category: Urology & Nephrology Authors: Cox A, Zhao C, Tolkach Y, Nettersheim D, Schmidt D, Kristiansen G, Hauser S, Müller SC, Ritter M, Ellinger J Tags: Urol Oncol Source Type: research

Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study.
CONCLUSIONS: Palliative interventions were seldom used among patients with advanced urologic malignancies. Palliative interventions were less frequently used in older patients and minority races. Further study is warranted to define the role of palliative interventions in advanced urologic malignancies and guide their utilization. PMID: 32430252 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 16, 2020 Category: Urology & Nephrology Authors: Lec PM, Lenis AT, Brisbane W, Sharma V, Golla V, Gollapudi K, Blumberg J, Drakaki A, Bergman J, Chamie K Tags: Urol Oncol Source Type: research

Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
CONCLUSION: These results suggest that MAPT may be a promising predictive biomarker for survival and play an essential role in bicalutamide resistance in CaP. PMID: 32430253 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 16, 2020 Category: Urology & Nephrology Authors: Sekino Y, Han X, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Shiota M, Takeshima Y, Yasui W, Matsubara A Tags: Urol Oncol Source Type: research

Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.
CONCLUSIONS: Patients with HG UTUC who achieve ypT0-1 stage after NAC exhibit favorable oncologic outcomes comparable to those inherently non-muscle-invasive who do not receive chemotherapy. Improvements in clinical staging will play an important role in better defining candidacy for NAC in treating HG UTUC while minimizing overtreatment. Furthermore, pathologic stage may serve as an appropriate early surrogate for oncologic endpoints in designing clinical trials. PMID: 32430254 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 16, 2020 Category: Urology & Nephrology Authors: Singla N, Christie A, Freifeld Y, Ghandour RA, Woldu SL, Clinton TN, Petros FG, Robyak H, Yeh HC, Fang D, Enikeev D, Bagrodia A, Sagalowsky AI, Lotan Y, Raman JD, Matin SF, Margulis V Tags: Urol Oncol Source Type: research

Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members.
Abstract PURPOSE: The American Urological Association (AUA) introduced evidence-based guidelines for the management of nonmuscle invasive bladder cancer (NMIBC) in 2016. We sought to assess the implementation of these guidelines among members of the Society of Urologic Oncology (SUO) with an aim to identifying addressable gaps. METHODS AND MATERIALS: An SUO approved survey was distributed to 747 members from December 28, 2018 to February 2, 2019. This 14-question online survey (Qualtrics, SAP SE, Germany) consisted of 38 individual items addressing specific statements from the AUA NMIBC guidelines within 3 br...
Source: Urologic Oncology - May 16, 2020 Category: Urology & Nephrology Authors: Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM Tags: Urol Oncol Source Type: research

The world is only ten years old: The dawn of artificial intelligence in urologic oncology.
PMID: 32417110 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 14, 2020 Category: Urology & Nephrology Authors: Loughlin KR Tags: Urol Oncol Source Type: research

Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
CONCLUSION: Our simplified substratification might contribute to improving predictive accuracy on intravesical recurrence, MIBC and metastasis progression, and cancer-specific mortality in patients with primary high-risk NMIBC who underwent TURBT. PMID: 32417111 [PubMed - as supplied by publisher] (Source: Urologic Oncology)
Source: Urologic Oncology - May 14, 2020 Category: Urology & Nephrology Authors: Fujita N, Hatakeyama S, Momota M, Tobisawa Y, Yoneyama T, Yamamoto H, Imai A, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C Tags: Urol Oncol Source Type: research